MetaCap

iBio (IBIO) vs Kazia Therapeutics (KZIA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

iBio (IBIO) has outperformed Kazia Therapeutics (KZIA) over the past year, losing 23.8% versus a loss of 41.1%. Over five years, KZIA leads with a -99.0% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($56.4 million vs $56.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBIO-23.80%KZIA-41.08%
+204%+76%-53%
Nov 21, 20251 yearNov 20, 2026
IBIO-99.76%KZIA-99.13%
+7%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBIO versus KZIA key metrics
MetricIBIOKZIA
Share price$0.8001$4.92
Market cap$56.37M$56.22M
1-day change-0.11%-8.38%
YTD return-58.54%-28.59%
1-year return-23.80%-41.08%
5-year return-99.76%-99.01%
EPS (TTM)$-0.27$-6.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$100.00K—
Revenue growth (YoY)-75.00%—
Net income (latest FY)$-33.04M—
Operating margin-35141.00%—
Net margin-33044.00%—
52-week high$3.82$17.40
52-week low$0.68$4.50
Distance from 52-week high-79.05%-71.72%
Analyst consensusstrong_buynone
Avg. price target upside+611.16%+476.02%
Average volume678.91K307.30K
Shares outstanding70.46M11.43M
Employees236
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IBIO has outperformed KZIA by 17.3 percentage points over the past year.

About iBio

IBIO stock →

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Kazia Therapeutics

KZIA stock →

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

IBIO vs KZIA FAQ

Which is bigger, iBio or Kazia Therapeutics?

iBio (IBIO) is larger, with a market capitalization of $56.37M compared with $56.22M for Kazia Therapeutics (KZIA).

Which stock has performed better over the past year, IBIO or KZIA?

IBIO returned -23.80% over the past 12 months, compared with -41.08% for KZIA (price return, excluding dividends). Past performance does not predict future results.

Are iBio and Kazia Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons